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time promote AR degradation? Since PI3KIAkt signaling promotes AR degradation, PTEN inhibition of this pathway would be expected to result in increased AR protein levels. It is possible that PTEN can go through both pathways by inhibition of PI3K/Akt-mediated AR degradation by the 26 S proteasome and caspase-3-mediated AR degradation. Yet the overall balance may favor the caspase-3-mediated AR degradation.
Aim 3: To determine whether Akt can suppress androgen/AR-induced cell growth inhibition and apoptosis.
(See Mol. Endo manuscript) The loss of PTEN expression in prostate LNCaP cells leads to constitutive activation of Akt (1) . Akt is an important survival factor in a variety of cell types including LNCaP cells. Several lines of evidence have indicated that PI3K/Akt is able to suppress cell apoptosis induced by growth factor deprivation (2, 3, 4) . Abrogation of PI3K/Akt activity by P13K inhibitors causes LNCaP cell apoptosis (5, 6) . On the other hand, the androgen/AR signal is thought to play important roles in the prostate cancer cell growth and survival, and this signal can protect cells from apoptosis in response to treatment of P13K inhibitors (5, 7). Thus, the PI3K/Akt and the androgen/AR signaling pathways represent two major survival pathways in the LNCaP prostate cancer cells. As PTEN could repress the androgen/AR signal and PI3K/Akt pathway in LNCaP cells, we propose that inhibition of these two pathways by PTEN might contribute to PTEN-induced cell apoptosis in the LNCaP prostate cancer cells. This assertion was further supported by the observation that restoration of AR function or the PI3K/Akt pathway rescues cells from PTEN-induced apoptosis (Fig. 3) . 
+
Akt can suppress androgen-induced apoptosis in this cell model by inhibiting androgen receptor through directly phosphorylating androgen receptor. The rest of the studies were done in prostate cancer LNCaP cells, in which loss of PTEN expression leads to constitutive activation of Akt (1) . Akt is an important survival factor in a variety of cell types. P13K and Akt is able to suppress cell apoptosis induced by growth factor deprivation (2, 3, 4) . Abrogation of PI3K/Akt activity by P13K inhibitor causes LNCaP cell apoptosis (5, 6) . On the other hand, the androgen/AR signal is though to play important roles in the prostate cancer cell growth and survival, and this signal can protect cells from apoptosis in response to treatment of P13K inhibitors (5, 7) . In our submitted paper, (J. BioL Chem, Induction of AR expression by FOXO3a, and their roles in apoptosis of LNCaP cells) , we found P13K inhibitor did not lead to cell death but cell arrest under normal growth media culture conditions. Knockdown of AR by transfection of AR siRNA causes 51% of the cells to enter sub-G1 phase. Transfection of AR siRNA plus P13K inhibitor further induces cell apoptosis; 65.7% cells underwent apoptosis. (Fig. 4D) . Thus, the PI3K/Akt and the androgen/AR signaling pathways represent two major survival pathways in LNCaP prostate cancer cells. Aim 4: To .generate site-specific phospho-AR antibodies and use these Abs to monitor the AR phosphorylation status and their relationship to the progqression of prostate cancer. Several site-specific phospho-AR antibodies were tested for their specificity and to determine appropriate and efficient testing concentrations and procedures. However these prepared antibodies proved to be ineffective and/or inefficient. Last year we were hoping to have additional antibodies available for testing and studies on archival human tissue samples could proceed after the evaluations of the antibodies are completed. Unfortunately after several trials and experiments we found most of these antibodies were also ineffective and/or inefficient.. The only one that works is an anti-phospho-AR (ser 210 ) antibody. The anti-phospho-AR (ser 2 1 0 ) antibody (clone 156C135.2) was generated from the phospho-AR peptides (SGRAREADGAPTSSKD) according to the manufacturer's procedures (Androscience, San Diego, CA). As shown in Fig. 2B and 2C (See J. Biol. Chem. manuscript), The anti-phospho-AR (ser21 0 ) antibody was used in the western blot analysis to support our hypothesis that activation of the PI3K/Akt pathway induces AR phosphorylation in vivo.
KEY RESEARCH ACCOMPLISHMENTS:
9 Via a PI3K/Akt-dependent pathway PTEN regulates AR activity in high passage number LNCaP cells. e PI3K/Akt pathway promoted AR ubiquitylation, leading to AR degradation by the 26 S proteasome. * Via a PI3K/Akt-independent pathway PTEN suppresses androgen receptor (AR) activity in the early passage number of prostate cancer LNCP cells. e Restoration of AR function or the PI3K/Akt pathway rescues cells from PTEN-induced apoptosis 9 * Site-specific antibodies evaluated with poor results, however others are in process of being developed, which also proved to be unsuccessful antibodies, with one exception as noted above in Aim 4. 
CONCLUSIONS:
As a summary, we ask how to interpret these findings and what is the physiological role of increased AR function after PI3K/Akt is blocked? We found that removal of androgens in LNCaP cells resulted in increased levels of active phosphorylated Akt. Thus, we believe that the AR and PI3K/Akt signaling both appear to be important proliferation and survival factors in prostate cancer cells, and seem to antagonize each other to maintain the cell homeostasis. The AR activity can be induced by LY294002 to play a dominant proliferation role to compensate for the loss of PI3K/Akt signaling. Our additional studies in 2003 led us into studies involving the PTEN pathway and its relationship to our Akt studies. Although we had expected to have tissue studies with antibodies by now, we find we are unable to complete and barely started these studies due our failure to find suitable effective antibodies with the one exception as noted above in Aim 4. The phosphatidylinositol 3-kinase (PI3K)/Akt path-activation of the PI3K/Akt pathway protects cells from apoptoway controls several important biological functions, sis induced by serum starvation and androgen deprivation (2) . such as cell growth regulation, apoptosis, and migraRecent rapid progress of the PJ3K/Akt signal pathway studtion. However, the way in which PI3IJAkt controls an-ies, as well as its influence on the androgen receptor (AR)-drogen receptor (AR)-mediated prostate cancer cell mediated prostate cancer growth, has resulted in many excitgrowth remains unclear and controversial. Here, we ing yet controversial results.
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Here we address these demonstrate that the PI3K/Akt pathway regulates AR controversial results by summarizing Akt-AR-related results activity in a cell passage number-dependent manner. and provide new data, as well as possible explanations for the Specifically, PI3K/Akt pathway can suppress AR activity distinct roles of the PI3K/Akt pathway in AR-mediated prosin androgen-dependent LNCaP cells with low passage tate cancer growth. Particular emphases will be: 1) Akt supnumbers. In contrast, it can also enhance AR activity in presses versus induces AR activity, 2) Akt phosphorylation LNCaP cells with high passage numbers. Furthermore, sites on AR protein, and 3) promotion afAR degradation by the we also demonstrate that insulin-like growth factor-1 sitesnAR pathway. can activate the PI3K/Akf pathway that results in the PI3K/Akt pathway. phosphorylation of AR at Ser 2 10 and Ser 7 90 . The consequence of these events may then change the stability of AR protein.
Together, our results demonstrate that the Reagents-pCDNA3 cAkt (3) and mutant AR S21OA/S790A were PI3K/Akt pathway may have distinct mechanisms to described previously (4). pCDNA3-PTEN was a gift from Dr. Charles L.
Sawyers, and pGEX-KG-PTEN was from Dr. Frank B. Furnari. Insulinmodulate AR functions in various stages of prostate can-like growth factor-1 (IGF-1) and LY294002 was from Calbiochem. 5a-cer cells and that a combined therapy of antiandrogens Dihydrotestosterone (DHT), doxycycline (Dox), and cycloheximide were and anti-PI3K/Akt inhibitors may be worth considering from Sigma. The anti-AR polyclonal antibody, NH27, was produced as as a future therapeutic approach to battle prostate described previously (3) . The mouse monoclonal PTEN and prostatecancer.
specific antigen (PSA) antibodies and the goat polyclonal A-actin antibody were from Santa Cruz Biotechnology. The mouse monoclonal Akt and phospho-Akt (Ser 4 73 ) antibodies were purchased from Cell Signaling. Prostate cancer is the second leading cause of cancer-related Cell Culture and Transfections-DU145, PC-3, and COS-1 cell lines death among men in the United States. The normal prostate were maintained in Dulbecco's minimum essential medium containing and prostate cancers at early stages require androgen for penicillin (25 units/ml), streptomycin (25 gg/ml), and 10% fetal calf growth and survival. In addition to androgen signaling, which serum (FCS). LNCaP cells were maintained in RPMI 1640 with 10% plays an essential role in survival of prostate cancer, the phos-FCS. Transfections were performed using SuperFect" TM according to phatidylinositol 3-kinase (P13K)'/Akt pathway represents anstandard procedures (Qiagen). othertimplortanto surivalsePIgnal/for proatehcanreprells.Its a Luciferose Reporter Assays-Luciferase reporter assay was as deother important survival signal for prostate cancer cells, it scribed previously with some modifications (5). The cells were transappears that these two pathways can compensate for each fected with plasmids in 10% charcoal-stripped serum (CSS) medium for other in growth regulation of prostate cancer LNCaP cells, 16 h and then treated with ethanol or 10 nm DHT for 16 h. The cells because androgen treatment can rescue cells from apoptosis were lysed, and luciferase activity was detected by the dual luciferase induced by application of P13K inhibitors (1) . Furthermore, assay according to standard procedures (Promega). Mouse mammary tumor virus-luciferase (MMTV-luc), which contains the AR response elements, was used as an AR transactivation reporter. The results were normalized by Renilla luciferase activity (pRL-SV40-luc), and the data * The work was supported by National Institutes of Health Grant represent means ± S.D. from triplicate sets of three independent DK60905 and a George Whipple Professorship endowment. The costs of experiments. publication of this article were defrayed in part by the payment of page LNCaP Stable Transfectants--For the Dox-inducible system, PTEN charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
was released from pGEX-KG-PTEN using EcoRe digestion and inserted ¶ To whom correspondence should be addressed. E-mail: chang@ into pBIG2i vector. The LNCaP cells were transfected with pPIB2i urmc.rochester.edu; Website: wnw.urmn.rochester.edu/ChangARcab.
PTEN for 24 h. The cells were selected using 100 p•g/ml hygromycin.
'The abbreviations used are: P13K, phosphatidylinositol 3-kinase; Individual colonies were picked and grown until 70% confluent followed AR, androgen receptor; cAkt, constitutively active form of Akt; CSS, by 4 gtg/ml Dox treatment. The positive clones were confirmed by charcoal-stripped serum; DHT, 5a-dihydrotestosterone; Dox, doxycy-Western blot analysis. )-The phospho-AR serum; IGF, insulin-like growth factor; MMTV-luc, mouse mammary peptide (SGRAREADGAPTSSKD) was generated and used for generation tumor viriis-luciferase; PSA, prostate-specific antigen; PTEN, phosphaof anti-phospho-AR (Serm') antibody (clone 156C135.2) according to the tase and tensin homolog deleted on chromosome ten.
manufacture's procedures (AndroScience, San Diego, CA). (Fig. 1A, P25 ) but enhanced AR the CSS medium (Fig. IF) , suggesting that the androgens are activity in high passage number LNCaP cells (Fig. 1B, P60) , in important for cell growth. In contrast, high passage LNCaP reporter gene assays. It should be noted that the reporter gene cells, with higher basal Akt activity, grew much faster than activation by androgen was much higher in higher passage early passage LNCaP cells (Fig. 1F) , suggesting less dependLNCaP cells (Fig. 1, compare panel B with A) . The reason for ence on the androgens. Elevation of the basal Akt activity by this phenomenon is currently unknown. This may suggest that transfection of cAkt significantly increased the LNCaP cell some factors that preferentially exist or are over-expressed in growth at both cell passages, although the effect of cAkt was higher passage LNCaP cells may contribute to the enhancemore profound in the early passage LNCaP cells (Fig. 1F) . ment of this androgen response. Blockage of the P13K/Akt Thus, the Akt signal may be a key factor in driving LNCaP cell pathway by LY294002 slightly enhanced AR activity in low growth and survival at this late stage with weaker androgen passage number LNCaP cells but suppressed AR activity in reliance. high passage number LNCaP cells (Fig. 1,A 
and B, 4th lanes on
Considering the biphasic effect of PI3KJAkt and androgen right). Although LY294002 has been widely used as a P13K signaling on the progression of prostate cancer, we found that inhibitor, we cannot rule out the possibility that at 20 pM this androgen ablation therapy, which removes most of the androreagent may affect other kinases that influence AR activity. We gens available for prostate tumors, may result in increased performed a Western blot assay to examine the role of the activation of fhe PI3K/Akt pathway, promoting tumor cell PI3K/Akt pathway in regulating AR target gene expression.
growth and survival. This hypothesis is further supported by a Even though LY294002 only marginally enhanced AR activity recent report (11) showing that the P13K/Akt pathway is elein low passage LNCaP cells in the reporter gene assays ( (Fig. 1C) .
reason, using a combination therapy that includes androgen Moreover, cAkt reduced androgen-induced PSA expression in ablation at early stages and suppression of the P13K/Akt pathlow passage number LNCaP cells but slightly enhanced PSA way at later stages may provide a better strategy for battling expression in high passage number LNCaP cells (Fig. ID) . prostate cancer. These results suggest that distinct passage numbers of LNCaP
The Effect of PI3KIAkt Signaling on AR Phosphorylationcells might influence the effects of the P13K/Akt effect on AR AR is a phosphoprotein, and its activity can be modulated by activity. Using PC-3 cells, Thompson et al. (9) also demonphosphorylation (12) . We demonstrated that activation of strated that the P13K/Akt pathway could suppress AR activity, P13K/Akt pathways by IGF-1 in COS-1 cells induces AR phoswhich is consistent with our data (Fig. 1A) and with early phorylation in vivo (3). The in vitro kinase assay further rereports using DU145 cells as the cell model (3 mutant (dAkt), induced AR phosphorylation in vivo, and mu-ation. In contrast, IGF-1 did not induce phosphorylation of the tations at the consensus serine residues reduced Akt-mediated mutant AR (S21OA/S790A), in which two Akt consensus sites AR phosphorylation (3). Consistent with our results, Wen et al. were mutated from Ser to Ala (Fig. 2D, tntAR) . These data (7) also found that Akt associated with AR and phosphorylated therefore strongly support our early findings that the PI3K/Akt AR at Ser 210 It is therefore possible that the level of the Akt activity in LNCaP cells. They also found that P13K inhibitor LY294002 LNCaP cells may not be sufficient to induce AR activity, given did not change the levels of AR phosphorylation in a two-that the basal level of Akt activity is low in early passage dimensional gel electrophoresis assay (13) . These contrasting LNCaP cells ( explanation for the discrepancy may be that the overexpression way-AR controls several biological functions, including prosof Akt via transient transfection may produce protein levels tate cell growth and apoptosis (12) . However, the mechanism that are far higher than that seen under physiological by which AR maintains its stability for proper function remains conditions. largely unknown. Growing evidence implies that AR may be To determine whether gene overexpression was a confound-degraded by the ubiquitin-proteasome pathway (15) (16) (17) . In ing factor in the interpretation of our AR phosphorylation support of this notion, we have recently demonstrated that assays, we used IGF-1 to activate endogenous PI3K/Akt and activation of the PI3K/Akt pathway induces AR ubiquitylation therefore mimic physiological conditions. As shown in Fig. 2A, and subsequent degradation by the 26 S proteasome (4). The we demonstrated that IGF-1 treatment induced AR phospho-effect of Akt on AR ubiquitylation and degradation seems to be rylation in LNCaP cells (passage number 38), and adding the dependent on AR phosphorylation, because activation of Akt P13K inhibitor LY294002 blocked IGF-1-mediated AR phos-did not induce ubiquitylation or degradation of mutant AR, phorylation, suggesting that the PI3K/Akt pathway is involved which lacks Akt-mediated phosphorylation. Interestingly, the in the phosphorylation of AR. Using a site-specific anti-phos-AR mutant was remarkably stable compared with wild-type phoserine AR antibody, AR phosphorylation at Ser 2 l° was de-AR, suggesting that phosphorylation of AR by Akt reduces AR tected when LNCaP cells were treated with IGF-1 (Fig. 2B) . stability (4) . Moreover, using the Dox-inducible system we generated the Mdm2, a Ring Finger protein, consists of an E3 ligase and inducible PTEN clone, a tumor suppressor that antagonizes the suppresses p53 activity by regulation of ubiquitylation and PI3K/Akt pathway (14) , in LNCaP cells at passage number 40. degradation of p53 (18, 19) . In addition to regulation of p53 PTEN expression induced by Dox treatment inhibited Akt ac-function, Mdm2 can also regulate AR activity via regulation of tivation and AR phosphorylation at Ser 210 (Fig. 2C) . IGF-1 also ubiquitylation and degradation of the AR (4). We further ideninduced wild-type AR phosphorylation in COS-1 cells (Fig. 2D , tified Mdm2 as an E3 ligase for AR and a mediator for AktwtAR), and LY294002 blocked the IGF-1-mediated phosphoryl-induced AR ubiquitylation and degradation (4 THE ANDROGEN RECEPTOR (AR), a transcription reproductive organs and in progression of prostate factor, belongs to the nuclear receptor superfamily cancer (3) (4) (5) . Maximal or proper androgen action may (1, 2). Once bound to androgen, AR translocates into require the interaction of AR with several coregulators the nucleus, leading to activation of its target genes (6), such as ARA70 (7, 8) , ARA55 (9, 10), ARA54 (11, (3) . AR consists of the amino-terminal region that is 12), and steroid receptor coactivator-1 (13). involved in transcriptional activation, the DNA-binding
The tumor suppressor gene PTEN (phosphatase domain (DBD), the hinge region that contains the nuand tensin homolog deleted on chromosome 10), loclear localization signal, and the ligand-binding docated at chromosome 10q23, is one of the most fremain (LBD) that is involved in androgen binding and quently mutated genes linked to a variety of human receptor dimerization (3). It is generally accepted that cancers (14) (15) (16) (17) (18) (19) (20) PC-3, and LNCaP cells, but to a lesser extent (Fig. 1A) . Recent studies demonstrated that PTEN regulates
To rule out the possibility that the suppression of AR not only cell growth and apoptosis, but also controls by PTEN might come from the suppressive effect of cell adhesion and migration (28) (29) (30) . Whereas the PTEN on general transcriptional machinery, we used PTEN sequence suggests that it may be a dual specpGL3-control vector (Promega Corp., Madison, WI) ificity phosphatase that includes lipid phosphatase and pG5-Lucifase (a GAL4 reporter) as controls to and protein phosphatase activity, its protein substrates demonstrate that PTEN has little or enhanced effect on remain largely unknown. Recently, several groups have these control luciferase vectors after being normalized reported that the phosphatidylinositol-3-OH kinase with pRL-SV40 internal control used in all samples (PI3K)/Akt pathway is negatively regulated by PTEN (Fig. 1 B) . Northern blot analysis further confirmed that through its phospholipid 3-phosphatase activity (16, 17, PTEN could suppress androgen-induced expression 31-33). Whereas the P13K/Akt-dependent pathway is the of prostate-specific antigen, an endogenous AR target most popular model for PTEN action, other signaling gene, in prostate cancer LNCaP cells (Fig. 1C ). pathways were also suggested (34). For instance, It is generally believed that PTEN exerts its role in dPTEN regulates cell growth and proliferation in Drotumor suppression by negatively regulating the P13K/ sophila through the PI3K/Akt-dependent and -indepenAkt pathway. We next determined whether PTEN afdent pathway (34). Furthermore, using mouse embryonic fects AR activity via the regulation of the PI3K/Akt fibroblasts (MEFs) from PTEN-null mice, Wu and copathway in different passage numbers of LNCaP cells. workers (35) . showed that PTEN can physically interact
The protein expression levels of AR and Akt are comwith p 5 3 and regulate protein stability and transcriptional parable between the low and high passages of LNCaP activity without its phosphatase activity, indicating that cells, but the basal Akt activity in high passage number PTEN regulates p53 function independent of the P13K/ LNCaP was much higher than in low passage number Akt pathway. As a consequence, loss of one allele of LNCaP cells (Fig. 1 D) . Interestingly, in a low passage PTEN dramatically accelerates tumor formation of the number of LNCaP cells (passage 25), PTEN supp53 heterozygous mouse.
presses AR activity via a PI3K/Akt-independent pathAs androgen/AR plays important roles in prostate way, as addition of the constitutively active form of Akt cancer progression, understanding the factors in-(cAkt) does not reverse the suppressive effect of PTEN volved in the regulation of androgen/AR action may on AR activity ( Fig. 1 E, left panel, lane 4) . Interestingly, provide molecular targets for prostate cancer treatcAkt, like PTEN, also suppressed AR activity in low ment. Here we demonstrate that PTEN regulates AR passage number LNCaP cells ( Fig. 1 E, left panel, lane activity in low-passage number LNCaP cells via a 5). PI3K/Akt inhibitor, LY294002, did not significantly PI3K/Akt-independent pathway and interacts directly enhance AR activity ( Fig. 1 E, left panel, lane 6) perhaps with AR to suppress androgen-induced AR nuclear due to a low basal activity of Akt in such cells (Fig. 1 D) . translocation. The interaction between AR and PTEN However, restoration of Akt activity completely remay expose the active site of the AR for the recogniversed the PTEN suppression of AR activity in high tion of caspase-3, leading to AR degradation. In conpassage number LNCaP cells ( Fig. 1 E, Because PTEN regulates AR activity via a P13K/Aktlinkage between PTEN and androgen/AR signaling. To independent pathway in the early-passage LNCaP test this hypothesis, we determined the effect of the cells, we hypothesized that PTEN might function via PTEN on AR transactivation using mouse mammary direct interaction with AR. Indeed, our glutathione-Stumor virus-luciferase (MMTV-luc) as an AR reporter.
transferase (GST) pull-down assay results indicated PTEN suppressed AR transactivation in a dosethat PTEN could interact with AR in the presence or dependent manner in androgen-dependent prostate absence of androgen ( Fig. 2A) . Among several nuclear LNCaP cells and in androgen-independent prostate receptors we tested, we found that PTEN binds prefcancer PC-3 cells and DU145 cells (Fig. 1A) . Interesterentially to AR and estrogen receptor (ER), as comingly, PTEN C124S, a PTEN mutant without phosphapared with glucocorticoid receptor (data not shown), progesterone receptor (data not shown), or the retin-1-107) or GST-PTEN-no. 3 (aa 253-403) (Fig. 2 , B and oid X receptor ( Fig. 2A) . C). Further peptide mapping revealed that PTEN-PTP To map the AR interaction domains on PTEN, the (aa 110-163) containing the phosphatase domain is plasmids encoding a set of PTEN fragments fused with sufficient for interacting with AR (Fig. 2C ). GST were constructed for the GST pull-down assays.
Studies of the PTEN-interacting domain on AR indiThe AR Was able to interact with GST-PTEN-no. (aa 666-91 8), were able to interact with PTEN (Fig. 2, cycline (Dox)-inducible system. Dox treatment in-D and E). The GST pull-down assay results therefore duced expression of PTEN or PTEN C124S in several suggest that AR can interact with PTEN (aa 110-163) clones (PTEN-C1, PTEN-02, PTEN 0124S-04, and via its DBD (aa 552-651). PTEN C124S-C8, Fig. 3A) . AR could be coimmunoTo further confirm the physiological interaction beprecipitated with PTEN, when we used cell lysates tween AR and PTEN by coimmunoprecipitation, we from PTEN-Cl cells (Fig. 3B3) 
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PTEN
The interaction between PTEN and AR was also analyzed by the subcellular colocalization study, using 
PTEN Decreases AR Protein Levels via Promotion
expression of PTEN in LNCaP PTEN-C1 and PTEN-C2 of AR Degradation reduced endogenous AR protein levels. In contrast,
Dox-induced PTEN C124S expression in PTEN-
To determine whether PTEN suppression of AR trans-C124S-C4 and PTEN-C124S-08 failed to reduce enactivation involves the modulation of AR protein stadogenous AR protein levels. Together, our data clearly bility, we assessed the transient transfection and demonstrate that PTEN could interact with AR and Western blot analyses. We found that PTEN could reduce AR protein levels in COS-1 and LNCaP cells.
reduce AR protein levels in COS-1 cells (Fig. 5A ). To
To determine whether the reduced AR protein 1ev-rule out the possibility that PTEN may influence the els were due to reduced mRNA expression, a porpromoter activity of the AR expression plasmid, we tion of each LNCaP cell lysate was subjected to tested the expression of endogenous AR in PTEN-.
Northern blot analysis. Whereas AR protein levels stable LNCaP cells. As shown in Fig. 5B , Dox-inducedl were reduced by Dox-induced PTEN, the AR mRNA 
IM -AR+PTEN LNCaP p38
(1-actin
---vector S]methionine for 45 min in the presence of 10 nM DHT and harvested at different chase times as indicated. The cell extracts were immunoprecipitated with AR antibody and subjected to SDS-PAGE followed by autoradiography. The intensity of the bands was quantitated using ImageQuant (Molecular Dynamics, Inc., Sunnyvale, CA). Data were from three identical results. D, Early-passage LNCaP cells at passage 38 (p38) were transfected with or without PTEN in 10% CDS media for 16 h, pulsed with cyclohexamide (CHX) treatment in the presence of 10 nM DHT, and then harvested at different chase times as indicated. The cell extracts were Western blotted with AR, PTEN, and P-actin antibodies. E, PTEN-regulated AR degradation is inhibited by Akt in high-passage number LNCaP cells. LNCaP cells at passage 65 (p65) were transfected with plasmids, as indicated, for 24 h, treated with 10 nM DHT for another 24 h, and harvested for Western blot assay. (*, P < 0.05; **, P < 0.001 vs. AR alone, Student's two-tailed t test) levels normalized by /3-actin remained relatively unthe phenomenon that PTEN promotes AR degradation changed (data not shown), suggesting that PTEN may via the non-PI3K/Akt pathway, the stability of the enreduce the AR protein levels through posttranscripdogenous AR in the early-passage LNCaP cells (pastional modification. sage 38), where the PTEN effect on AR is suggested to We then studied AR protein stability by pulse chase be independent of the P13K/Akt pathway ( Fig. 1 E) , was labeling. As shown in Fig. 5C, PTEN clearly reduced clearly reduced in the presence of PTEN (Fig. 5D) . the half-life of newly synthesized [3S]AR 4-to 5-fold These data strongly suggest that other pathways, and accelerated AR degradation. Interestingly, when such as direct PTEN-AR protein-protein interaction, we replaced PTEN with either the dominant negative may play major roles for the PTEN-promoted AR degform of Akt (dAkt) or P13K inhibitor LY294002, the radation. In contrast, in high passage number LNCaP results (data not shown) indicated that dAkt and cells (passage 65) where the P13K/Akt pathway be-LY294002 did not promote AR degradation, ruling out comes dominant (Fig. 1, D and E) , PTEN-induced AR the possibility that PTEN promotes AR degradation via degradation was suppressed by cAkt (Fig. 5E ), sugregulation of the PI3K/Akt pathway. In agreement with gesting that the suppressive effect of PTEN on AR involves the Akt pathway and Akt might not promote suppression of AR transactivation by PTEN (Fig. 6 , B and AR ubiquitylation and degradation in high-passage C), on PTEN-induced apoptosis in LNCaP cells (passage LNCaP cells.
35). As expected, PTEN could induce apoptosis markIt has been suggested that PTEN regulates the staedly, whereas PTEN C124S showed only a marginal bility of p27k"Pl via a ubiquitin-proteasome pathway effect, and AR-D markedly reduced PTEN-induced (38) . Whereas MG1 32, a proteasome inhibitor, blocked apoptosis (Fig. 6F) . The suppressive effect of AR-D on estrogen-mediated ER degradation (see supplemental PTEN functions was not due to the interference of PTEN Fig. 1A, right panel, published as supplemental data phosphatase activity, because AR-D showed little influon The Endocrine Society's Journals Online web site ence on the PTEN-mediated inhibition of Akt activity at http://mend.endojournals.org), it did not prevent (data not shown). Together, these data clearly suggest PTEN-mediated AR degradation (see supplemental that interaction between PTEN and AR contributes to Fig. 1 A, left panel) , suggesting that PTEN promotes AR PTEN-induced suppression of AR functions and apoptoprotein degradation via a proteasome-independent sis. Our results (Fig. 6F ) also confirmed an earlier report pathway. Interestingly, we found that the caspase-3 (39a) that PTEN-induced cell death could be reversed by inhibitor DEVD-CHO, can block PTEN-mediated AR adding cAkt, suggesting that the PTEN---P13K--> Akt degradation (see supplemental Fig. 1 B) . We demonpathway also plays a role in the mediation of PTENstrated that caspase-3 could cleave AR into three induced cell death. evident fragments, and DEVD-CHO completely
To rule out the possibility that AR-D may have nonblocked caspase-3-mediated AR degradation (see specific effects, we used glioblastoma U87MG cells to supplemental Fig. 1 B) , consistent with the previous test the effects of AR-D on the PTEN-induced apoptoreports (39) .
sis in AR-negative cells. Both Western blot assay and AR transactivation assay indicated that AR was undeInteraction between PTEN and AR Contributes to tectable in U87MG cells (data not shown). Whereas PTEN-Induced Suppression of AR Functions PTEN induced apoptosis in U87MG cells, the addition and Apoptosis of AR-D showed only marginal effects on the PTENinduced apoptosis, and cAkt suppressed PTENTo further prove that PTEN suppression of AR function induced apoptosis (data not shown). These results may go through direct PTEN-AR interaction, we used suggest that the effect of AR-D on PTEN-induced AR-D, which can interact with PTEN and disrupt the apoptosis is specific and requires the intact AR siginteraction between AR and PTEN in the CWR22R naling. Together, results from Fig. 6 clearly indicate cells (Fig. 3D) , for functional studies. Our results furthat PTEN may have two distinct pathways ther showed that AR-D could dramatically reduce (PTEN--PI3K/Akt and PTEN-->AR) to induce apopto-PTEN-mediated inhibition of AR nuclear translocation sis, and the interaction of PTEN with AR may play (Fig. 4E) , PTEN-mediated promotion of AR degradaimportant roles in one of these two pathways in the tion (Fig. 6A) , and PTEN-mediated suppression of AR -LNCaP prostate cancer cells. transactivation (Fig. 6B) , suggesting that PTEN and AR interaction plays important roles for the PTEN effects Inhibition of Endogenous PTEN Expression on AR nuclear translocation, AR protein degradation, Increases AR Protein Levels and and AR transactivation. To extend our studies of PTEN Transcriptional Activity on the suppression of AR function, we applied AR-D to another prostate cancer cell line, CWR22R, which exWe have demonstrated that overexpression of PTEN presses functional AR and PTEN (36, 37) . As shown in promotes AR degradation and suppresses AR activity. Fig. 6C , PTEN dramatically suppressed AR transactiTo avoid the above observations resulting from overexvation. Remarkably, AR-D could significantly reduce pression, we used small interfering RNA (siRNA) to block PTEN suppressive effect on AR transactivation (Fig. endogenous PTEN and examined whether the AR pro-6C). Furthermore, the PTEN mutant devoid of AR bindtein levels and transcriptional activity would be affected ing region (A aa121-200, PTEN-dPTP) failed to supby down-regulating PTEN. As shown in Fig. 7A , transient press AR expression (Fig. 6D) and transactivation (Fig. transfection of PTEN siRNA into human embryonic kid-6E). These results therefore are in agreement with the ney 293T cells reduced endogenous PTEN protein levels results from LNCaP cells (Fig. 613) and suggest that up to 50-60%, which correlated with the transfection PTEN may be able to modulate AR functions by direct efficiency (-50%) in our experiment conditions. As exinteraction with AR in the various stages of prostate pected, reduction of PTEN expression enhanced AR cancers.
protein expression in the presence and absence of anThe PTEN tumor suppressor induces cell apoptosis in drogen (Fig. 7A) . PTEN siRNA enhanced AR transaca variety of cell types including the LNCaP cells. To tional activity in a dose-dependent manner in the presdetermine whether suppression of AR activity by PTEN ence of androgen in 293T cells (Fig. 7B) . Furthermore, we contributes to PTEN-induced apoptosis, we used the observed that the levels of AR protein expression in TUNEL (terminal deoxynucleotidyltransferase-mediated PTEN-null MEFs were much higher than that in WT MEFs deoxyuridine triphosphate nick end-labeling) assay to (Fig. 7C) , suggesting that AR may be more stable in the study the effect of AR-D, which could partially relieve absence of PTEN. The LNCaP cells were transfected with indicated plasmids in 10% CDS media for 16 h, followed by treatment with 10 nM DHT for 24 h. Cells were then harvested, and the cell extracts were subjected to Western blotting with anti-AR or anti-Akt antibody. B, The LNCaP cells were transfected with indicated plasmids in 10% CDS media for 16 h, followed by treatment with 10 nM DHT for another 16 h. Cells were harvested and assayed for MMTV-luciferase activity. C, The CWR22R cells were transfected with plasmids, as indicated, using (ARE)4-luc as a reporter for 16 h, followed by ethanol or 10 nMa DHT treatment for another 16 h. Cells were harvested for luciferase assay. 0, The 293T cells cultured in DMEM containing 10% FCS were transfected with pCDNA3-AR, pCDNA3-FLAG-PTEN, pCDNA3-FLAG-PTEN-dPTP, and/or pEG+P-C1 (BD Biosciences, Franklin Lakes, NJ), as indicated, for 24 h, and harvested. The cell extracts were subjected to SOS-PAGE. Western blot analysis was performed, and AR and PTENs were detected by AR and FLAG antibodies, respectively. Enhanced green fluorescent protein expression was used for transfection and loading control. E, The CWR22R cells were transtected with plasmids, as indicated, using (ARE)4-luc as a reporter for 16 h, followed by ethanol or 10 nMa DHT treatment for another 16 h. Cells were harvested for luciferase assay. F, The LNCaP cells were transfected with plasmids, as indicated, for 16 h, and the medium was changed to 0.1% CDS media for 2 d. The cell apoptosis was determined by TUNEL assay. PTEN, but not PTEN-no. 1 (aa 1-'107) or mutant PTEN-C1 24S, induced LNCaP cell apoptosis. Increased AR expression by transfection of AR, interrupting PTEN-AR interaction by AR-D, and overexpressing cAkt could rescue LNCaP cell apoptosis caused by PTEN. Data for luciferase activity and apoptosis are means -+ 5D from three independent experiments. *, P < 0.05; **, P < 0.001 vs. control (indicated as 0), Student's two-tailed t test.
MEFs drastically reduced AR protein levels, as corn-DISCUSSION pared with that in WT MEFs (Fig. 70) . We also found that AR transcriptional activity in PTEN-null MEFs was much
The PTEN tumor suppressor induces cell apoptosis in higher than in WT MEFs, and reconstitution of PTEN in a variety of cell types including the prostate cancer PTEN-null MEFs significantly suppressed AR activity cells. However, the molecular mechanism underlying (Fig. 7D) . cAKt did not reverse the PTEN-mediated re-PTEN-induced apoptosis in prostate cancers remains pression of AR activity (Fig. 7D) , suggesting that PTEN largely unknown. In the present study we have identisuppresses AR activity via the PI3K/Akt-independent fied AR as a novel target of PTEN in vitro and in vivo. pathway in MEFs. These results suggest that endoge-PTEN inhibited AR nuclear translocation, promoted AR nous PTEN is a negative regulator for controlling AR protein degradation, and inhibited AR transactivation protein stability and transcriptional activity, via direct PTEN-AR interaction. We also demonstrated that PTEN-induced suppression of AR transactivation complex in the cytoplasm, which may then make AR and apoptosis could be inhibited by interruption of more vulnerable to enzymatic degradation. PTEN and AR interaction by adding AR-D peptide.
Sequence analysis indicates that AR contains the Furthermore, using the PTEN siRNA and PTEN-null nuclear localization signal (NLS) (aa 617 to 633) in the MEFs we found that AR protein levels and transcriphinge region between DBD and LBD. It has been retional activity were elevated. Taken together, these ported that mutations in the NLS may lead to the results indicate that PTEN is a negative regulator for disruption of AR nuclear translocation (42) . It is plaucontrolling the AR activity and that interaction between sible that PTEN binds to the hinge region of AR result-AR and PTEN may play an important role for PTEN to ing in the interruption of the NLS nuclear translocation. suppress AR and induce apoptosis in prostate cancer Alternatively, PTEN could simply compete with other cells.
AR coregulators for binding to the same region, causLike other members of the steroid receptor supering the inhibition of the nuclear translocation. family, AR may move dynamically between the nuRecent reports suggest that PTEN may exert its cleus and the cytoplasm (40) . As androgen induces AR biological activity by regulating stability of proteins. nuclear translocation and prolongs the half-life of AR For example, PTEN can regulate the ubiquitin-depen-(41), it is generally accepted that AR degradation might dent degradation of CDK inhibitor p27KiP1 through the be prevented by binding androgen and translocating ubiquitin E3 ligase SCFSkP2 (38) . PTEN can also atteninto the nucleus. Because PTEN suppresses AR nuuate the hypoxia-mediated HIF-1 a (hypoxia-inducible clear translocation and promotes AR degradation, it is factor 1) stabilization (43) . Together with our finding possible that these two events occur subsequently showing that PTEN promotes AR degradation, these and are functionally linked. It is likely that PTEN may results support a role of PTEN in modulation of protein first bind to AR, leading to retention of this PTEN-AR degradation. Proteins containing the PEST sequence are thought to be the target proteins for ubiquitination Because the interaction between PTEN and AR and degradation (44) . As AR contains the PEST seplays an important role in PTEN-meaiated AR degraquence (aa 638 to 658) in the hinge region (45) , it is dation (Fig. 5A) , it is possible that PTEN binding to AR possible that PTEN accelerates AR degradation may be required to expose the active site of the AR for through the ubiquitin-proteosome pathway via the caspase-3 recognition, thus leading to AR degrada-PEST sequence. However, this hypothesis is not suption. This hypothesis is supported by the demonstraported by our result showing that PTEN-induced AR tion that some apoptosis inducers, such as staurodegradation is not affected by the treatment of the sporine and phorboester (phorbol myristate acetate), proteasome inhibitor MG132 (see supplemental Fig. can induce caspase-3 activation (48, 49) , but fail to 1A), suggesting the unlikelihood that PTEN goes induce AR degradation (data not shown) (50). through the ubiquitin-proteasome pathway to promote A mutant PTEN C124S, which does not have phos-AR degradation. As the caspase-3 inhibitor completely phatase activity, exhibits a significantly reduced ability blocked the effect of PTEN on AR degradation (see to suppress AR activity in LNCaP and DU145 cells, supplemental Fig. 1A ), caspase-3 may mediate the indicating that PTEN phosphatase activity is important PTEN-induced AR degradation. This hypothesis is furfor PTEN-mediated AR suppression. Given that PTEN ther supported by our result (see supplemental Fig. directly interacts with AR and that its phosphatase 1 B) and the earlier report showing that caspase-3 activity is important for its effect on AR activity, it is could degrade AR in vitro (39) . It has been reported possible that PTEN may regulate AR activity via direct that PTEN-induced apoptosis can be rescued by dephosphorylation of AR. However, we were unable to caspase-3 inhibitor in LNCaP cells (46) , which also detect a significant change in AR phosphorylation strengthens our hypothesis that PTEN signaling can upon addition of GST-PTEN in an in vitro dephosphorbe mediated through caspase-3 via direct cleavage of ylation assay (data not shown). These data raise the AR protein (39) . Although our study demonstrates that possibility that PTEN may regulate AR activity, in part, PTEN-mediated AIR degradation is through caspase-3 via indirectly affecting the phosphorylation status of activity (see supplemental Fig. 1 ), we found that the other proteins. repression of AIR activity by PTEN could not be res-
The loss of PTEN expression in prostate LNCaP cued by a caspase-3 inhibitor or a general caspase cells leads to constitutive activation of Akt (15). Akt is inhibitor (see supplemental Fig. 1 C) . These contrasting an important survival factor in a variety of cell types inhitorsee splemenatal Fuppressig. 1 C). These singh including LNCaP cells (15) . Several lines of evidence results imply that PTEN suppression of AR might go have indicated that PI3K/Akt is able to suppress cell through multiple pathways, and caspase-3-mediated apoptosis induced by growth factor deprivation (16, degradation could be one of these pathways. In addi-52). in of t activity tby P 1i b tion, because it has been known that caspase-3Abrogation of P3K/Akt activity by P3K inhibclecavese Aiat the D1b51residue, weowntheratcaspitors causes LNCaP cell apoptosis (53, 54) . On the cleaves AR at the D151 residue, we further tested the other hand, the androgen/AR signal is thought to play effect of PTEN on AR-Di51N mutant. We found that ipratrlsi h rsaecne elgot n PTEN can still repress the transactivation of ARimportant roles in the prostate cancer cell growth and D151N (see supplemental Fig. 1D) , indicating that survival, and this signal can protect cells from apopto-D151N(e suppressedAnotaonly viga protindegdation. t sis in response to treatment with P13K inhibitors (54, PTEN suppressed AR not only via protein degradation. 55). Thus, the PI3K/Akt and the androgen/AR signaling Because PTEN-dPTP (lacking AR interacting domain) pathways represent two major survival pathways in failed to suppress AR transactivation (Fig. 6E) and the LNCaP prostate cancer cells. As PTEN could re-AR-D (interaction inhibitor) can block the suppressive press the androgen/AR signal and PI3K/Akt pathway effect of PTEN on AR transactivation (Fig. 6 , A-C and in LNCaP cells, we propose that inhibition of these two F), it is possible that in addition to degradation of AR, pathways by PTEN might contribute to PTEN-induced direct association between AR and PTEN may also cell apoptosis in the LNCaP prostate cancer cells. This contribute to suppression of AR activity, assertion was further supported by the observation We reported recently that the PI3K/Akt pathway that restoration of AR function or the PI3K/Akt pathpromoted AR ubiquitylation, leading to AR degradaway rescues cells from PTEN-induced apoptosis tion by the 26 S proteasome (47) . These data clearly (Fig. 6F ). suggest that both PTEN and the P13K/Akt pathway Consistent with the reporter gene assay (Fig. 1E , can promote AR degradation via distinct mechanisms.
right panel), in the high-passage number LNCaP cells How can PTEN negatively regulate the PI3K/Akt pathwe found that PTEN could down-regulate AR protein way and at same time promote AR degradation? Belevels and this effect was reversed by Akt (Fig. 5E ). cause PI3K/Akt signaling promotes AR degradation, Furthermore, Akt did not down-regulate AR protein PTEN inhibition of this pathway would be expected to levels (Fig. 5E ), suggesting that Akt might not promote result in increased AR protein levels. It is possible that AR ubiquitylation and degradation in high-passage PTEN can go through both pathways by inhibition of LNCaP cells. Based on our data we propose a model P13K/Akt-mediated AR degradation by the 26 S profor PTEN action on AR signaling in prostate cancer teasome and caspase-3-mediated AR degradation.
LNCaP cells. PTEN regulates AR activity in lowYet the overall balance may favor the caspase-3-passage LNCaP cells via a PI3K/Akt-independent mediated AR degradation.
pathway and interacts directly with AR to suppress androgen-induced AR nuclear translocation. The in-MATERIALS AND METHODS teraction between AR and PTEN might expose the active site of the AR for the recognition of caspase-3.
Constructs and Reagents The PTEN activated caspase-3 then recognizes the AR and leads to AR degradation (Fig. 8) . Although pCDNA3-cAkt and pCDNA3-dAkt were from Dr. R. Freeman.
overexpression of the active form of Akt can inhibit LY294002, DEVD-CHO, and z-VAD-FMK were from Calbio-PTENI-induced caspase-3 activation, thus potentially chem (La Jolla, CA). 5Y-Dihydrotestosterone (DHT) and Dox were from Sigma Chemical Co. (St. Louis, MO). The anti-AR blocking PTEN-mediated AR degradation, Akt itself polyclonal antibody, NH27, was produced as previously decan induce AR degradation. This may explain why scribed (8, 56 In low-passage number LNCaP cells, the P13K/Akt pathway suppresses AR activity and induces AR ubiquitylation and degradation by 26S proteasome (47) . PTEN tumor suppressor also suppresses AR activity at this early-passage number of LNCaP cells via a PI3K/Akt-independent pathway. PTEN directly interacts with AR and induces caspase-3 activation. The interaction between AR and PTEN may lead AR to expose the active site for caspase-3 recognition, resulting in AR degradation. Furthermore, the interaction between AR and PTEN results in suppression of AR nuclear translocation. However, the PI3K/Akt enhances AR activity in high-passage number LNCaP cells via an unknown mechanism. PTEN, on the other hand, suppresses AR activity via a PI3K/Akt-dependent pathway.
(25 ,ig/ml), and 10% fetal calf serum (FCS). The LNCaP, were washed four times with PBS, followed by application U87MG, and CWR22R (a gift from Dr. C. Kao) cells were of the counting medium containing 4',6-diaminodino-2-maintained in RPMI-1640 with 10% FCS. Transfections were phenylindole. Coverslips were examined by confocal microperformed using the calcium phosphate precipitation method scope. A FITC-conjugating antimouse antibody and a Texas in PC-3 and DU145 cells, as previously described (57) or Red antirabbit antibody were used as secondary antibodies. SuperFect in LNCaP, COS-1, and U87MG cells according to standard procedures (QIAGEN, Chatsworth, CA).
LNCaP Stable Transfectants
Apoptosis Assay For the Dox-inducible system, PTEN or PTEN C124S were released from pGEX-KG-PTEN or pGEX-KG-PTEN C124S using EcoR/ digestion and inserted into pBIG2i vector. The For the apoptosis assay, the cells were transfected with LNCaP cells were transfected with pBIG2i vector, pPIB2i plasmids for 24 h and grown in 0.1% charcoal dextran-PTEN, or pBIG2i PTEN C124S for 24 h. The cells were sestripped serum (CDS) media. The apoptosis was determined lected with 100 pg/ml hygromycin B. Individual colonies were 2 d after transfection using the TUNEL assay according to the picked up and grown until 70% confluent, followed by 4 standard procedures (Oncogene Science, Inc., Manhasset, pkg/mu Dox treatment for 48 h. The positive clones were NY). At least 200 cells were scored for each sample, and data confirmed by Western blot analysis. are means ± sD from three independent experiments.
Pulse-Chase Experiments Luciferase Reporter Assays
Pulse-chase experiments were performed as described (60) The cells were transfected with plasmids in 10% CDS media with some modifications. Briefly, COS-1 cells were transfor 16 h and then treated with ethanol or 10 nM DHT for 16 h.
fected with pSG5-AR in combination with pCDNA3 or The cells were lysed and the luciferase activity was detected pCDNA3 PTEN in 10% CDS media for 36 h. Cells were grown by the dual luciferase assay according to standard proceunder serum starvation conditions for 2 h in methionine/ dures (Promega). The results were normalized by pRL-SV40 cysteine-deficient medium, and then the cells were pulsed for activity, and the data are represented as means -SD from at 45 min with 200 tCi/ml [ 3 5 S]methionine/cysteine (NEN Life least three independent experiments. Science Products, Boston, MA). Cells were washed with DMEM twice and incubated with DMEM containing 0.2% CDS along with 10 nM DHT. The cells were lysed by RIPA Glutathionine-S-transferase (GST) Pull-Down Assay buffer in the presence of protease inhibitors, followed by immunoprecipitation using AR antibody. The immunocomThe GST pull-down assay described previously (58) was perplexes were subjected to 8% SDS-PAGE and visualized by formed with some modifications. GST-fusion proteins were autoradiography. purified as described by the manufacturer (Amersham Pharmacia Biotech). The purified GST-proteins were resuspended Construction of PTEN siRNA with 100 pl of interaction buffer [20 mM Tris-HCI (pH 8.0), 60 mM NaCI, 1 mm EDTA, 6 mm MgCI 2 , 1 mmc dithiothreitol, 8%
A small-interfering RNA (siRNA) was expressed in mammaglycerol, 0.05% (vol/vol) Nonidet P-40, 1 mm phenylmethyllian cells by transfection of a DNA-based vector BS/U6 (61) sulfonyl fluoride, and protease inhibitors] and mixed with 5 Al containing a homologous sequence (CCCACCACAGCTAof 35 S-labeled TNT proteins in the presence or absence of 1 GAACTTATC), a 6-bp spacer (CTCGAG), an inverted homolpM ligands on a rotating disk at 4 C for 2 h. After extensive ogous sequence (GATAAGTTCTAGCTGTGGTGGG), and 5 washes with NENT buffer (20 nM Tris-HCI/pH 8.0, 100 mM "T"s, at the transcription initiation site of the U6 promoter. NaCI, 6 mm MgCI 2 , 1 mm EDTA, 0.5% (vol/vol) Nonidet P-40, 1 mM dithiothreitol, 8% glycerol, 1 mM phenylmethylsulfonyl
